Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Lawitz

Showing results (101-110 of 157) with videos related to

Pageof 16
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver|December 11, 2019
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infectionEric Lawitz, Robert Flisiak, Manal Abunimeh, et al.
Journal of Hepatology|October 25, 2023
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directionsVlad Ratziu, Marcus Hompesch, Mathieu Petitjean, et al.
The New England Journal of Medicine|January 20, 2012
Preliminary study of two antiviral agents for hepatitis C genotype 1Anna S Lok, David F Gardiner, Eric Lawitz, et al.
Hepatology Communications|February 7, 2018
The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatmentEdward J Gane, Sophie Metivier, Ronald Nahass, et al.
The New England Journal of Medicine|January 17, 2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1Kris V Kowdley, Eric Lawitz, Fred Poordad, et al.
Hepatology (Baltimore, Md.)|September 12, 2017
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trialRohit Loomba, Eric Lawitz, Parvez S Mantry, et al.
Plos One|May 30, 2013
A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infectionDavid Gardiner, Jay Lalezari, Eric Lawitz, et al.
Medicine|April 28, 2025
The accuracy of FibroScan, FIB-4, and nonalcoholic fatty liver disease fibrosis score in predicting biopsy-defined fibrosis and steatosis across all fibrosis stages in patients with metabolic dysfunction associated steatotic liver diseaseKeerthi Thallapureddy, David Twitchell, Kristen Ott, et al.
Gastroenterology|June 15, 2016
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and SofosbuvirChristoph Sarrazin, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
Pageof 16

Showing results (101-110 of 157) with videos related to

Sort By:
Pageof 16
Liver International : Official Journal of the International Association for the Study of the Liver|December 11, 2019
Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infectionEric Lawitz, Robert Flisiak, Manal Abunimeh, et al.
Journal of Hepatology|October 25, 2023
Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directionsVlad Ratziu, Marcus Hompesch, Mathieu Petitjean, et al.
The New England Journal of Medicine|January 20, 2012
Preliminary study of two antiviral agents for hepatitis C genotype 1Anna S Lok, David F Gardiner, Eric Lawitz, et al.
Hepatology Communications|February 7, 2018
The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatmentEdward J Gane, Sophie Metivier, Ronald Nahass, et al.
The New England Journal of Medicine|January 17, 2014
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1Kris V Kowdley, Eric Lawitz, Fred Poordad, et al.
Hepatology (Baltimore, Md.)|September 12, 2017
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trialRohit Loomba, Eric Lawitz, Parvez S Mantry, et al.
Plos One|May 30, 2013
A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infectionDavid Gardiner, Jay Lalezari, Eric Lawitz, et al.
Medicine|April 28, 2025
The accuracy of FibroScan, FIB-4, and nonalcoholic fatty liver disease fibrosis score in predicting biopsy-defined fibrosis and steatosis across all fibrosis stages in patients with metabolic dysfunction associated steatotic liver diseaseKeerthi Thallapureddy, David Twitchell, Kristen Ott, et al.
Gastroenterology|June 15, 2016
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and SofosbuvirChristoph Sarrazin, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
Pageof 16